Learn peptides step by step

GLP-1s and Muscle Health: What the Latest Meta-Analysis Means for Body Recomposition

GLP-1 weight loss is not the same as automatic muscle loss. The real story depends on protein, resistance training, and tracking.

Retatrutide and Food Noise: Why Appetite Control Changes Adherence

The scale is only part of the story. Retatrutide's biggest advantage may be how it quiets food noise and makes adherence easier to sustain.

GLP-1 Muscle Preservation: How to Keep Lean Mass While Losing Fat in 2026

GLP-1s can drive impressive weight loss, but the real win is losing fat without giving up strength. This guide shows how to protect lean mass while appetite is down.

Retatrutide Is Approaching Surgery-Level Weight Loss: What the New Data Actually Means

Retatrutide's weight-loss signal is now strong enough that people are comparing it with surgery. That comparison is useful, but only if you understand what the numbers do and do not mean.

GLP-1s and Breast Cancer Risk: What the New Signal Means

GLP-1 research is moving beyond weight loss. New breast cancer risk and survival signals are interesting, but they need careful interpretation.

CagriSema and Amylin: Why GLP-1 Stacks Are Changing in 2026

GLP-1 therapy is no longer just GLP-1. CagriSema, cagrilintide, petrelintide, and amycretin show why amylin is becoming a serious metabolic target.

GLP-1s and Macular Degeneration: What the Eye Studies Say

GLP-1 research is moving beyond weight loss. Recent ophthalmology studies suggest possible links with age-related macular degeneration, but the signals are mixed and need careful interpretation.

GLP-1s Before Bariatric Surgery: What the 2026 Evidence Says

GLP-1 peptides are changing the bariatric surgery conversation. The practical lesson is not self-managing around surgery. It is better tracking, clearer handoffs, and coordinated medical planning.

Retatrutide TRIUMPH-1 Phase 3 Results: How to Track the 28.3% Weight Loss Data

The new TRIUMPH-1 readout gives retatrutide users a clearer dose-response map: 4 mg, 9 mg, and 12 mg all worked, but the tolerability tradeoffs matter.

Dapiglutide: What the GLP-1/GLP-2 Obesity Trial Means

Dapiglutide is not another simple GLP-1 copycat. The early 2026 trial missed statistical significance for weight loss, but the mechanism points toward the next phase of peptide design.

GLP-1 Discontinuation: How to Maintain Weight Loss After Stopping

A 2025 Biomolecules review highlights the hardest GLP-1 question: what happens after the weight comes off? Maintenance needs a plan before the final dose.

Injectable Peptide Safety Checklist: What Doctors Want Patients to Know in 2026

AMA and FDA updates make one thing clear: peptide interest is moving faster than human evidence, dosing standards, and product-quality controls. Use this checklist before trusting a vial.

GLP-1 Lean Mass Loss: What 2026 Data Shows

A new 2026 meta-analysis puts real numbers on lean mass change during semaglutide, tirzepatide, and liraglutide weight loss. The practical takeaway is not panic. It is better tracking.

Retatrutide Trials in 2026: Back Pain, Liver, Heart, and Muscle Signals to Watch

Retatrutide is no longer just a weight-loss headline. Current 2026 trial records show researchers testing broader questions: pain, liver disease, cardiorenal risk, dose escalation, and lean-mass preservation.

Efsubaglutide Alfa SUPER1 Trial: What the New GLP-1 Data Shows

Efsubaglutide alfa is a long-acting GLP-1 receptor agonist with new human trial data in drug-naive type 2 diabetes. Here is what the SUPER1 results actually show.

Retatrutide TRIUMPH-4: 28.7% Weight Loss and Osteoarthritis Relief in One Peptide

The TRIUMPH-4 trial delivers groundbreaking dual benefits: 28.7% body weight reduction plus significant osteoarthritis pain relief. Retatrutide's triple mechanism may solve two problems simultaneously.

Retatrutide Trial Participant Hit 31% Total Body Weight Loss: What the Number Actually Means

31% body weight loss in a trial participant. Not an average — an individual result. But when 39.4% of Phase 3 participants on the 12mg dose hit the same milestone, the outlier becomes a pattern.

Retatrutide Phase 3 Results: 28.7% Weight Loss Sets New Standard

New Phase 3 data shows Retatrutide nearly doubled the weight loss results of current GLP-1 drugs without hitting a plateau.

GLP-1 for Weight Loss Without Diabetes: What the 2026 Systematic Review Found

You don't need to have diabetes to benefit from GLP-1 therapy. A comprehensive 2026 systematic review confirms what the peptide community has known for years — and the results are striking.

Retatrutide Not Working for Weight Loss? Here's What to Check

You've been on Retatrutide for 4-6 weeks and the scale hasn't budged. Before you give up or double your dose, here are the real reasons Reta might not be 'working' — and what to actually do about it.

Switching from Tirzepatide to Retatrutide: The Complete Transition Guide

Already on tirzepatide and considering retatrutide? Here's exactly how to make the switch—starting doses based on your current Tirz level, what the glucagon component changes, and how to avoid common transition mistakes.

Retatrutide Dosing for Beginners: Your First 12-Week Titration Schedule

Retatrutide is one of the most powerful GLP-1/GIP/glucagon receptor agonists available. But starting at the wrong dose — or jumping up too fast — is the #1 beginner mistake. Here's the complete titration roadmap.

PolicyAdvanced

Oral GLP-1s Are Here: What the Foundayo FDA Approval Means for the Peptide Community

For years, GLP-1 therapy meant a weekly injection. The FDA just changed that. Foundayo is the first oral GLP-1 approved for weight management, and the implications for the peptide community go far beyond convenience.

Retatrutide Cuts Knee Pain by 75.8%: What the TRIUMPH-4 Trial Means Beyond Weight Loss

Everyone focused on the 71-pound weight loss stat from TRIUMPH-4. But the buried finding — 75.8% reduction in knee pain scores — may be the more important number for anyone living with joint pain.

Why Your Weight Isn't Moving on Retatrutide (And What to Do About It)

Hitting a plateau on Retatrutide is common and usually temporary. Here's the science behind GLP-1 stalls and the practical steps to break through them.

BRP Peptide: Stanford's AI-Discovered 'Natural Ozempic' Explained

A Stanford AI tool screened 2,600 uncharacterized peptides and identified BRP — a 12-amino acid molecule that cuts food intake by up to 50%, promotes fat burning, and avoids the nausea, constipation, and muscle loss common with GLP-1 drugs. Here's what the research actually shows.

11m

Why Retatrutide is Winning: Clinical Data Shows 28% Superior Fat Loss Over GLP-1

A 2026 meta-analysis comparing retatrutide to GLP-1 (Ozempic/Wegovy) and tirzepatide shows retatrutide delivers 28% superior fat loss. Here's the science behind why the triple-agonist approach is reshaping weight loss and body recomposition.

Peptide Stacking for Muscle Preservation on GLP-1s: The Complete Protocol

The biggest risk with GLP-1 weight loss drugs isn't the fat loss — it's the muscle you lose with it. Strategic peptide stacking can tip the balance toward true body recomposition.

Retatrutide TRIUMPH-4 Phase 3 Trial: 28.7% Body Weight Reduction Confirmed

Phase 3 data is in: retatrutide produced an average 28.7% body weight reduction — roughly 71 lbs — in the TRIUMPH-4 trial. Here's what the numbers mean and how the triple agonist mechanism drives these results.

Retatrutide TRANSCEND Trial: What the Phase 3 Data Actually Shows

TRANSCEND confirmed retatrutide as the most effective GLP-1 class compound tested in late-stage trials. 16.8% mean body weight reduction and a 2.0-point A1C drop in 40 weeks — here's what the full data shows.

14m

PeptidesAdvanced

Peptides for Longevity: The Emerging Science Behind Age-Reversal Compounds

The peptide space is shifting from weight loss toward longevity. Explore the science behind peptides designed to slow aging, repair cellular damage, and extend healthspan.

Start hereBeginner

Retatrutide Beginner's Guide: Reconstitution, Dosing & Getting Started

New to retatrutide? This guide covers everything: how much BAC water to add, dose calculations for common vial sizes, starting doses, and titration schedules for safe, effective results.

12m

Retatrutide vs Tirzepatide: What the Latest Clinical Data Shows

Retatrutide and tirzepatide dominate the peptide conversation, but they're not interchangeable. Here's what the latest clinical research reveals about their differences, efficacy, and mechanisms.

Retatrutide Shows 23% Superior Weight Loss vs Tirzepatide in Phase 3 Trial

Retatrutide, the triple-action GLP-1/GIP/glucagon receptor agonist, outperforms tirzepatide by 23% in the latest human clinical trial—the most comprehensive weight loss comparison to date.

Retatrutide: The Triple-Action Weight Loss Peptide Explained

Retatrutide is a next-generation weight loss peptide targeting three metabolic pathways. Here's how it works and why it outperforms earlier GLP-1 therapies.

12m

GLP-1 Agonists for Metabolic Health: Clinical Evidence & Body Recomposition Strategy

GLP-1 agonists have revolutionized metabolic health. Learn how these peptides work, their effects on metabolism, and how to use them strategically for body composition goals.

Retatrutide 2-Year Weight Loss Durability: What the Latest Data Shows

Retatrutide is showing remarkable 2-year durability for weight loss. Here's what the science says and what it means for your protocol.

11m

Semaglutide for Weight Loss: Complete Guide to GLP-1 Peptide Therapy

Explore how Semaglutide has revolutionized weight management through GLP-1 receptor agonism.

Tirzepatide: The Dual Agonist Revolution in Weight Loss

Discover why Tirzepatide's dual mechanism is producing record-breaking weight loss results in clinical trials.